OM1, Inc.

In our recent webinar, OM1, Inc. Founder Rich Gliklich explored exactly how AI-powered and decentralized technologies are raising the bar for regulatory-grade real-world evidence, from smarter patient identification to end-to-end auditability. If you're working on registries, observational studies, or RWE submissions, this is a good watch. Watch the webinar on demand today: https://okt.to/a05Npf

At the DIA Annual Conference on June 16th, OM1 Founder Rich Gliklich will tackle one of the most pressing questions in real-world evidence today: what makes a patient registry truly trustworthy? His session — "Patient Registries: Basket Trial or Basket Case?" — will examine how registries can remain nimble and opportunistic while meeting the growing demands for data quality, transparency, and auditability that regulators and payers require. If you'll be at DIA this year, don't miss this session.

Numbers don't tell the whole story. But they tell part of it. 1B+ patient-years powering PhenOM®, our AI foundation model. 10+ patents in AI and digital phenotyping. 300+ registries and observational studies designed. 130+ peer-reviewed publications across R&D, HEOR, Medical Affairs, and Commercial. 373M+ patients in our Real-World Data Cloud. Behind each of those numbers is a team that needed better evidence — regulatory submissions that needed to be supported, patient populations that needed to be found, post-market commitments that needed to be met without blowing the budget. Explore our case studies to see the stories behind the numbers: https://okt.to/lbq9EN

Tomorrow's the day. Are you registered? https://okt.to/m5Vg9o Join OM1, Inc., Hologic, Inc., and Novartis for a one-hour conversation on how AI is reshaping real-world evidence studies for regulatory purposes—with real-world examples. 📅 Tomorrow, May 20th | 12:00–1:00 PM ET Last chance to register → https://okt.to/gpDxKy

Halfway through day 1 of #ISPORAnnual and the exhibit hall is buzzing! Come by booth 1025 for a free patient finder assessment and a shortbread cookie - our team of epidemiologists, data scientists, and AI experts are ready for you!

Are patients with your condition of interest going undiagnosed right now? It's one of the most important questions in rare and under-diagnosed disease, and most organizations are working with incomplete answers. At ISPOR, we're offering a free PhenOM Patient Finder Assessment. Here's what you'll get: - An estimate of where likely undiagnosed patients with your condition of interest are in the U.S. today - Model performance stats so you know exactly how much to trust the numbers - Powered by PhenOM®, our real-world patient phenotyping platform built on one of the largest longitudinal datasets in healthcare No cost. Just a clearer picture of where undiagnosed patients may be hiding in plain sight. Fill out the form or stop by our booth for your free patient finder assessment at #ISPORAnnual. https://okt.to/nYo0Qs

If you're attending #ISPORAnnual next week in Philadelphia, we hope you'll stop by and see us. https://okt.to/NXF4sG The OM1 team will be at booth 1025 in the exhibit hall and we're looking forward to the kinds of conversations this conference does best: honest, substantive, and focused on where HEOR is actually headed. We work with life sciences companies, payers, and providers on some of the hardest problems in real-world evidence. If any of that is on your mind in Philadelphia, we'd love to hear about it. Book a dedicated meeting ahead of the show → https://okt.to/dW2nbh

Webinar: May 20th, 12pm ET. Register here: https://okt.to/KpksBG Registries and observational studies have long been essential tools for generating #RWE. But traditional approaches have struggled to balance rigor, efficiency, and scalability, especially at the extremes: massive population studies and rare disease programs with just dozens of patients. AI is changing that. Experts from OM1, Inc., Hologic, Inc., and Novartis will share how AI-powered methods are: ✅ Optimizing patient identification across large real-world networks ✅ Supporting rare populations with patient-mediated, decentralized tools ✅ Automating data acquisition and endpoint determination ✅ Building traceability and auditability that meets regulatory standards The conversation will be led by: Rich Gliklich, MD, Founder, OM1 Anne F. Rositch, PhD, MSPH, Senior Director, Health Outcomes and RWE, Hologic Julie Mouchet, PhD, Global Director of Evidence Generation and RWE at Novartis Hope to see you there on May 20th! Register here: https://okt.to/Pd6oyI

We're proud to share a milestone in real-world evidence for regulatory decision-making. OM1, Inc. helped power one of the largest real-world evidence studies ever submitted to the FDA — a 650,000-patient study that supported an approval for primary cervical cancer screening. What made this study possible at that scale? Automation, AI, and rigorous validation working together. Read more in the press release: https://lnkd.in/egDTWFMd

A lot of companies will tell you they have experts. And at #ISPORAnnual, you can see why OM1, Inc. experts have the record to prove it. Our team includes some of the most experienced epidemiologists, data scientists, AI researchers, and regulatory strategists working in real-world evidence today. And at ISPOR this year, our experts will be presenting research you won't want to miss. Find out what we're presenting and set up time to meet with our experts: https://okt.to/ki9xQo